Home›Stock Screener›Lasa Supergenerics›Financial Statements

Lasa Supergenerics Complete Financial Statements

11 Years of Data
2026 - 2016

In FY2026, Lasa Supergenerics (LASA) reported revenue ₹25 Cr, net profit ₹-35 Cr and EPS ₹-6.80, with a net profit margin of -140.0% and ROE of -41.7%. Full financial statements from FY2016 to FY2026 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see LASA share price screener.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin -140.00% 2026 data
EBITDA Margin -112.00% 2026 data
Operating Margin -113.00% 2026 data
Return on Assets -34.31% 2026 data
Return on Equity -41.67% 2026 data

Balance Sheet Ratios

Current Ratio 33.00 2026 data
Equity Ratio 82.35% 2026 data
Asset Turnover 0.25 2026 data

LASA Revenue, Net Profit & EBITDA — Year-on-Year Growth

LASA YoY (March 2025 vs March 2026) — revenue -83.1%, net profit -133.3%, EBITDA -354.5%, expenses -60.3%. Analyse LASA FII DII holdings to track promoter, FII and institutional holdings.

Revenue Growth
-83.1%
Year-over-Year
Net Profit Growth
-133.3%
Year-over-Year
EBITDA Growth
-354.5%
Year-over-Year
Expense Growth
-60.3%
Year-over-Year
Assets Growth
-32.5%
Year-over-Year
Equity Growth
-13.4%
Year-over-Year
Operating Cash Flow Growth
-250.0%
Year-over-Year
Financing Cash Flow Growth
-200.0%
Year-over-Year

LASA Income Statement — Revenue, EBITDA & Net Profit

Lasa Supergenerics revenue ₹25 Cr, EBITDA ₹-28 Cr, net profit ₹-35 Cr, EPS ₹-6.80 (2026) — net profit margin -140.0%. Also explore LASA stock price history to track price trends across different timeframes.

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016
Revenue 25 148 104 131 137 202 168 170 247 201 0
Expenses 54 136 102 136 121 155 137 159 202 153 0
EBITDA -28 11 2 -5 16 47 30 12 45 48 0
Operating Profit Margin % -113.00% 4.00% 2.00% -5.00% 12.00% 23.00% 18.00% 7.00% 17.00% 23.00% 0.00%
Depreciation 6 12 11 13 15 16 17 19 18 8 0
Interest 0 3 2 4 0 2 8 8 11 12 0
Profit Before Tax -35 -19 -19 -42 -6 30 5 -16 15 2 0
Tax 0 -5 3 -4 -1 7 1 -4 3 0 0
Net Profit -35 -15 -22 -39 -5 23 4 -12 12 2 0
Earnings Per Share (₹) -6.80 -2.95 -4.34 -7.71 -1.06 5.60 0.89 -5.26 5.43 1.15 0.00

LASA Balance Sheet — Assets, Liabilities & Shareholders' Equity

LASA total assets ₹102 Cr, total equity ₹84 Cr, total liabilities ₹ Cr (2025) — ROE -41.7%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
ASSETS
Total Assets 102 151 164 209 208 232 259 287 228 0
Current Assets 33 38 39 66 64 76 86 109 79 0
Fixed Assets 68 110 119 137 143 152 162 170 119 0
Capital Work in Progress 0 3 5 5 0 0 7 7 30 0
Investments 0 0 0 0 0 0 0 0 0 0
Other Assets 33 39 40 67 65 80 90 110 80 0
LIABILITIES
Total Liabilities
Current Liabilities 1 5 3 7 8 15 46 62 83 0
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 84 97 118 158 159 142 105 117 76 0
Share Capital 50 50 50 50 41 41 23 23 0 0
Reserves & Surplus 32 47 68 108 118 101 82 95 75 0

LASA Cash Flow Statement — Operating, Investing & Financing

Lasa Supergenerics operating cash flow ₹-3 Cr, investing ₹8 Cr, financing ₹-6 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016
Operating Activities -3 2 -17 9 41 14 41 40 -3 0
Investing Activities 8 0 11 -3 -4 -2 -7 -44 0 0
Financing Activities -6 -2 -4 0 -36 -10 -33 4 0 0
Net Cash Flow 0 0 -10 6 1 2 0 0 -3 0